Pharmaceutical Industry News Archive
Get news by email or subscribe to our news feeds.
News Archive for July 2012
July 2, 2012
- GSK and Theravance Announce Positive Results From Four Pivotal Phase III Studies for Once-Daily LAMA/LABA (UMEC/VI) in COPD
- AstraZeneca's £2bn Pledge to Tackle Diabetes
- AstraZeneca And Cellworks Collaborate to Find New Treatment for Tuberculosis
- Bristol-Myers Squibb and AstraZeneca Expand Diabetes Alliance Through Bristol-Myers Squibb's Acquisition of Amylin Pharmaceuticals
- Amylin Pharma Shares Climb
- AstraZeneca Partners With Bristol-Myers to Buy US Group Diabetes Specialist Amylin for $7bn
- Whistleblowers played major role in Glaxo case, leading to Glaxo's record settlement
- GlaxoSmithKline concludes previously announced agreement in principle to resolve multiple investigations with US Government and numerous states
- GlaxoSmithKline Pays $3bn to Settle US Investigation Into Its Marketing Practices
July 3, 2012
- Ampio Rises on Plans for Second Version of Zertane
- GlaxoSmithKline to Pay $3B in Settlement
- Icahn Challenges Forest Labs Decisions in Letter
- Chelsea Therapeutics Provides an Update on Northera (droxidopa) Regulatory Status and Development Program
July 5, 2012
- Biogen Idec and Sobi Initiate Global Clinical Trials of Long-Lasting Hemophilia A and B Product Candidates in Children
- Poll Finds 60 Percent of Physician Leaders Support Supreme Court Decision on ACA
- Cardiome Pharma Says CEO Janzen Left the Company
- FDA Sends Acorda Letter Over Ampyra Video
July 6, 2012
- Sucampo Pharmaceuticals Announces Arbitration Decision
- Pharmaceutical Firms to Get Incentives for Child Cancer Drugs
- Amgen Closes $315M Buyout of KAI Pharmaceuticals
- Salix Seeks Drug's Approval While Its Development Partner Fumes
- FDA Approves Genetic Test to Help Some Colon Cancer Patients, Physicians Considering Erbitux Therapy
- Lupin Receives FDA Approval for Generic Lyrica
July 9, 2012
- U.S. FDA Grants Priority Review for Xarelto (rivaroxaban) Supplemental NDAs for the Treatment of Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), and the Long-Term Prevention of Recurrent DVT and PE
- QLT Board of Directors Issues Letter to Shareholders Outlining New Corporate Strategy
- QIAGEN Achieves Personalized Healthcare Milestone with U.S. Approval of Companion Diagnostic for Colorectal Cancer
- PDS Biotechnology Corporation Signs Worldwide Licensing Agreement with Merck KGaA for Versamune
- Mass. Gov. Takes Bite Out of Medical Gifts Ban
- Suit Alleges Drug Firms Delayed Generic Lipitor
- FDA Oks Screening Test for Colon Cancer Drug
- Cardiome Announces Workforce Reduction
- Howard Solomon Sends Letter to Carl Icahn
- ERT Acquires invivodata to Establish the Industry's Most Experienced Provider of Clinical Outcome Assessment Solutions
July 10, 2012
- FDA Introduces New Safety Measures for extended-release and Long-acting Opioid Medications
- Abbott Announces New Test for the Management of Patients with Diabetes
- Ipsen's Partner Inspiration Biopharmaceuticals Announces Hold of Phase III Clinical Trials Evaluating IB1001 for the Treatment and Prevention of Hemophilia B
- Chelsea Therapeutics to Implement Corporate Reorganization
- Bristol-Myers Squibb Begins Tender Offer to Acquire Amylin Pharmaceuticals, Inc.
- CureBeta, a Collaboration between Evotec and Harvard University Enters Strategic Alliance with Janssen Pharmaceuticals
- Boehringer Ingelheim Pursuing Health Care Innovation ? New Collaboration with Healthrageous, Inc on a Digital Diabetes Self-management Program
- Chelsea Therapeutics Cutting Jobs, CEO Leaves
- Savient Pharmaceuticals Announces CEO Appointment and Reorganization Plan to Drive Long-Term Growth
- Bristol-Myers Squibb Starts Amylin Tender Offer
July 11, 2012
- Cangene Cancels IGIV Development Program
- Bristol-Myers to Invest $165M in Puerto Rico Plant
- Key Results Coming on 3 Drugs Against Alzheimer's
- Merck Pledging Funds to Reduce Maternal Mortality
- Update on Phase III Trial for Odanacatib, Merck's Investigational Cat-K Inhibitor for Osteoporosis
July 12, 2012
- IMS Study Forecasts Rebound in Global Spending on Medicines, Reaching Nearly $1.2 Trillion By 2016
- Actelion Announces Cost Saving Initiative to Be Implemented By the End of 2012
- Takeda and Affymax Announce Supply Agreement for Omontys (peginesatide) Injection with Fresenius Medical Care North America
- AstraZeneca Acquires Neuroscience Assets From Link Medicine
- CureBeta, a Collaboration Between Evotec and Harvard University Enters Strategic Alliance With Janssen Pharmaceuticals
- Merck Upgraded
- Ipsen?s Partner Inspiration Biopharmaceuticals Announces Hold of Phase III Clinical Trials Evaluating IB1001 for the Treatment and Prevention of Hemophilia B
- Global Spending on Drugs to Slow Through 2016
July 13, 2012
- The Nordic Group Acquires Rights to Trasylol From Bayer HealthCare
- Japanese Drug maker Moves Ahead With Local Expansion
- AVI Biopharma Is Now Sarepta
- Astra Zeneca Focuses on Brain Disease Treatments
- Ahead of the Bell: Ampio Pharmaceuticals
- Forest Laboratories Independent Directors Respond to Letter from Carl Icahn
- Watson's Generic Version of Plan B One-Step Receives FDA Approval
July 16, 2012
- UCB Launches Neupro in the U.S. to Treat Parkinson's Disease and Restless Legs Syndrome
- New J&J CEO to Discuss $20B Purchase in 2Q Report
- AstraZeneca Reports Terms of David Brennan?s Retirement
- Glaxo Closes in on Deal to Buy American Pharma Rival HGS
- GSK to acquire Human Genome Sciences for US$14.25 per share in cash
- States Bolstered By GlaxoSmithKline Settlement
- Alameda County Poised to Pass Drug Take Back Law After Months of Delay
- Hospira Injectable Drug Products: Recall - Visible Particulates from Defective Glass Vials
July 17, 2012
- AstraZeneca to Initiate a New Study of Brilinta (ticagrelor) in Patients with PAD
- Johnson & Johnson Reports 2012 Second-Quarter Results: Sales of $16.5 Billion decreased 0.7% Versus 2011 Second Quarter; Second-Quarter EPS was $0.50 Excluding Special Items, 2012 Second-Quarter EPS of $1.30 increased 1.6%*
- Chugai Expands in Singapore with Opening of Second Satellite Research Institute
- Forest Laboratories, Inc. Reports Fiscal Year First Quarter 2013 Earnings Per Share of $0.21
- Forest Laboratories, Inc. Reports Fiscal Year First Quarter 2013 Earnings Per Share of $0.21
- Promotional Trends Report from Encuity Research Shows Maneuvering to Fill Lipitor Vacuum
- Biogen Idec Announces Collaboration with Leading Research Institutions to Sequence Genomes of Patients with ALS
July 18, 2012
- Abbott Reports Strong Second Quarter Results
- FDA Schedules Advisory Committee Meeting for Insulin Degludec and Insulin Degludec/Insulin Aspart
- Top 100 Drug Sales Data Released - Plavix Leads the Way
- Sanofi Signs Agreement for Type 1 Diabetes Research with Boston Academic Teaching Hospital
- GlaxoSmithKline and Amicus Expand Partnership
- Johnson & Johnson Unit Cuts 200 Puerto Rico Jobs
- FDA Approves Weight-Management Drug Qsymia
- Abbott 2Q Profit Beats Expectations As Humira Sales Grow
July 19, 2012
- Baxter Reports Second Quarter Financial Results in Line with Guidance
- Novartis Second Quarter Results Enhance Future Growth Prospects With Eight Significant Regulatory Milestones; on Track to Deliver 2012 Outlook
- Actelion Announces Half Year 2012 Financial Results
- Amarin Execs to Receive Big Stock Bonuses
- Array BioPharma Achieves $8.5 Million Clinical Milestone in Amgen Diabetes Collaboration
- Physicians Interactive Announces New Zero-Click eCoupon Solution
- Infinity Regains Worldwide Rights to PI3K, FAAH and Early Discovery Programs
July 20, 2012
- Sanofi and Regeneron Launch Comprehensive Phase 3 Clinical Program With LDL Cholesterol-Lowering PCSK9 Antibody
- Isis Pharma Slumps Following Analyst Downgrade
July 23, 2012
- New Study Reveals Digital Differences between PAs, APRNs and RNs and Physicians and Key Opportunities for Marketers
- FDA: More Than 150 Antiretroviral Drugs Available Through PEPFAR for Worldwide HIV/AIDS Relief
July 24, 2012
- Biogen Idec Increases Revenue 18% to $1.4 Billion in the Second Quarter
- Chimerix Signs Worldwide License Agreement With Merck For CMX157, A Novel Candidate For The Treatment Of HIV
- Boehringer Ingelheim and Funxional Therapeutics Announce Acquisition of Funxional?s FX125L and the Somatotaxin Portfolio to Treat Inflammation
- Catalent Announces Commencement of Supply of Abilify Orally Disintegrating Tablets to Otsuka Pharmaceutical Co., Ltd. and Extensive Investments to Its Zydis Technology Capabilities in Swindon, UK
- Biogen 2Q Profit Climbs 34 pct, Avonex Sales Rise
July 25, 2012
- Lilly Reports Second-Quarter 2012 Results, Raises 2012 EPS Guidance
- Elan Reports Second Quarter and First Half 2012 Financial Results
- Antitrust: Commission Sends Statement of Objections to Lundbeck and Others for Preventing Market Entry of Generic Antidepressant Medicine
- Bristol-Myers Squibb's Second Quarter Highlighted by the Planned Strategic Acquisition of Amylin Pharmaceuticals and Important Clinical Data in Immuno-Oncology
- Lundbeck Disagrees With the Statement of Objections Issued By the European Commission
- Novavax Delays Testing on Flu Vaccine
- Drug May Treat Alzheimer's, Parkinson's
July 26, 2012
- Glaxo CEO Responds to Fraud-fine Questions
- Roche Profits Drop on One-off Costs
- Position of Merck Serono Concerning the Recommendation Made by CRCT of Geneva
- Sanofi CEO Chris Viehbacher Comments on Results for Q2 2012
- Doctors Petition FDA to Change Labeling of Painkillers
- Idenix Hepatitis C Drug Gets Fast Track FDA Review
- AstraZeneca: Second Quarter and Half Year Results 2012
- Roche posts strong operating first-half results; on track to meet 2012 guidance
- Sanofi: As expected, Q2 2012 Business EPS(1) impacted by the loss of exclusivity of Plavix(R) and Avapro(R) in the U.S.
- Regeneron Planning to Add 85 Jobs
July 27, 2012
- FDA Oks Horizon Pharma's Time-Release Painkiller
- Merck Announces Second-Quarter 2012 Financial Results
- Gilead Sciences Announces Second Quarter 2012 Financial Results
- Gilead Sciences Profit Slips on Acquisition Costs
- Merck's 2Q Net Falls on Charges, but Sales Rise
- Pennsylvania Court Upholds J&J Win on Risperdal Marketing
- Appeals Court Sides With Women Who Took Prempro
- Amgen's Second Quarter 2012 Revenues Increased 13 Percent To $4.5 Billion And Adjusted Earnings Per Share (EPS) Increased 34 Percent To $1.83
- Forest Pleased with Delaware Court's Decision on Icahn Litigation
July 30, 2012
- Antitrust: Commission Sends Statement of Objections on Perindopril to Servier and Others
- Merck Serono Announces Creation of First Spin-Off Company From its Entrepreneur Partnership Program
- Analyst Downgrades Eli Lilly
- Acura Pharmaceuticals Announces Update on AVERSION Products
- Monthly News Round Up - July 2012
July 31, 2012
- Pfizer Reports Second-Quarter 2012 Results
- Dendreon Announces Strategic Restructuring to Accelerate Path to Profitability and Future Growth
- Bayer Raises Guidance for the Full Year
- Intellipharmaceutics Settles Patent Litigation With AstraZeneca Concerning Generic Seroquel XR
- Idenix Pharmaceuticals Announces Restructuring of Development and Commercialization Collaboration With Novartis Pharma AG
